Gerngross, the associate provost of Entrepreneurship & Technology Transfer and a professor of bioengineering at Thayer School of Engineering, has started several biotech companies, including Adimab, the article notes. “It’s a great time to be in this space,” Gerngross tells The Scientist.
The first of Adimab’s antibody therapies is headed into clinical trials, the article notes. “Gerngross’s success is not only a tribute to his company’s technology, but an indication of the industry’s continued thirst for new antibodies,” the magazine writes.
Read the full story, published 9/1/13 by The Scientist.